Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ionis Pharmaceuticals Inc. Common Stock vs L3Harris Technologies Inc — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $42.5 (market cap $7.04B), while L3Harris Technologies Inc trades at $237.92 (market cap $43.71B). The key difference: L3Harris Technologies Inc is far larger — about 6.2× Ionis Pharmaceuticals Inc. Common Stock's market cap, and L3Harris Technologies Inc pays a 2.13% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and L3Harris Technologies Inc for 56 Days on average.
| IONS | LHX | |
|---|---|---|
Market Cap | $7.04B | $43.71B |
Volume | 2,977,440 | 1,558,148 |
Sector | Health | Industrials |
52-Week High | $86.50 | $378.48 |
52-Week Low | $42.38 | $233.63 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $6.60B | $54.15B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LHX trades at $237.50, down 0.31% with a bearish technical signal. The company shows solid fundamentals with consistent earnings beats, revenue growth from $21.3B to $21.9B (2024-2025), and a net income margin improving to 7.34%. Recent news includes a $6B THAAD propulsion contract but also multiple law firm investigations into investor claims, creating mixed sentiment.
Outlook: Strong defense budget tailwinds and recent contract wins support growth, but legal scrutiny and bearish technicals pose near-term risks. Analyst consensus is bullish with a $340 price target (43% upside), highlighting value if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ionis Pharmaceuticals Inc. Common Stock
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
